Introduction
============

Endocrine-disrupting chemicals (EDCs) are substances in the environment, food sources, and manufactured products that can interfere with the normal functioning of the body's endocrine system ([@r14]). EDCs include synthetized or natural hormones, pharmaceuticals, pesticides, and plasticizers that influence activity of estrogen receptors (ERs) ([@r23]). Diethylstilbestrol (DES) was the first orally active synthetic estrogen, and its use was intended to facilitate placental steroidogenesis and reduce the risk of spontaneous abortion or preterm parturition in pregnant women ([@r40], [@r41]). In clinical studies in 1971, DES was found to cause a rare vaginal tumor in young women exposed to this drug *in utero* ([@r19]; [@r25]). Almost immediately after the reports were published, the U.S. Food and Drug Administration blocked the use of DES for pregnancy support ([@r24]).

A mouse model of neonatal DES exposure has been widely used to study the possible effects of DES on the reproductive organs ([@r43]; [@r44]). This model system has also been used to help elucidate the mechanism(s) of hormonal carcinogenicity ([@r42]). Studies have indicated that female mice treated neonatally with DES develop a high incidence of uterine adenocarcinoma ([@r46]). Similarly treated male mice develop testicular cancer and abnormalities of the prostate and seminal vesicles (SVs) ([@r43]; [@r44]). Prins and colleagues reported that neonatal estrogen (E2) exposure induced lobe-specific alterations in the adult rat prostate, including a permanent decrease in androgen receptor (AR) levels ([@r50]; [@r53]). In a study using the neonatal DES model, [@r52] reported an abnormal morphology of the penis in male rats associated with changes in the protein levels of ERα, but not AR. In addition, neonatal DES exposure has been reported to significantly decrease the level of ERα protein in the anterior prostate but increase its level in the SV of male mice ([@r58]).

The biological effects of E2 and some EDCs are mediated through the ERs (ERα and ERβ), which are members of a large superfamily of nuclear receptors. These receptors act as ligand-inducible transcription factors ([@r20]). The classical mechanism of ER action is characterized by ER directly binding to estrogen response elements (EREs) of target genes. The nonclassical mechanism is the "tethered" mechanism, in which ERs regulate the expression of a large number of E2-responsive genes through interaction with other transcription factors, such as c-Jun, c-Fos, or Stat5 ([@r4]). EDCs regulate many target genes through the ER, similar to the regulation by E2 ([@r45]).

Seminal vesicle secretory protein IV (SVS4) is an androgen-dependent protein ([@r9]). The expression of the *Svs4* gene is dependent on the presence of testosterone in the rat SV ([@r27], [@r28]). Lactoferrin (or lactotransferrin; *Ltf* ) is a female-specific gene and serves as an appropriate marker of estrogenic action because of its high level of RNA and protein expression in E2-stimulated uteri compared with other tissues ([@r49]). Prenatal DES exposure studies have shown that the expression levels of the *Ltf* gene are induced in the SV of DES-treated mice ([@r48]).

Our research group has used the ER-knockout (ERKO) mouse to study ER-dependent pathways involved in mediating the effects of neonatal DES exposure in the reproductive tract tissues ([@r10]; [@r11]). Results of those studies demonstrated that ERα plays a critical role in mediating the toxicological effects of neonatal DES exposure in female and male reproductive tracts. In the prostate, E2 imprinting of the developing prostate gland was mediated through stromal ERα ([@r51]). In 4-month-old mice, neonatal DES exposure resulted in decreased SV weight in wild-type (WT) mice but not in αERKO mice ([@r12]; [@r51]). Recently, our laboratory reported that DES-induced SV toxicity and feminization were primarily mediated through ERα in adult mice ([@r61]).

DNA methylation is a well-characterized epigenetic modification and is important for gene regulation, transcriptional silencing, development, and tumorigenesis ([@r16]; [@r17]; [@r33]; [@r62]). In mammalian cells, DNA methylation occurs at the 5´ position of the cytosine ring within CpG dinucleotides via addition of a methyl group to create a 5´-methylcytosine. The methylation at the 5´-methylcytosine is catalyzed by DNA methyltransferases (DNMTs), including *DNMT1*, *DNMT3A*, and *DNMT3B* ([@r2]; [@r8]). The DNA methylation pattern is believed to be "read" by a conserved family protein, the methyl CpG binding domain (MBD) family ([@r30]; [@r59]). The MeCP2, MBD2, and MBD3 proteins belong to the MBD family and represent an important class of chromosomal proteins, which associate with protein partners that play active roles in transcriptional repression and/or heterochromatin formation ([@r60]). The second well-known epigenetic mechanism is histone modification, which is critical for regulating chromatin structure and function ([@r31]; [@r39]). Histone deacetylases (HDACs) 1 and 2 are highly conserved enzymes that help regulate chromatin structure as the core catalytic components of corepressor complexes ([@r6]). To date, studies indicate that these epigenetic markers play an important role in transcriptional programs during development. However, the correlation between DNA methylation and gene expression, as well as the involvement of these epigenetic markers, in response to EDC exposure are still poorly understood.

In the present study, we used a neonatal mouse model of DES exposure to examine the changes of DNA methylation patterns in the altered androgen-dependent gene *Svs4* and in the estrogen-dependent gene *Ltf*, as well as the correlation of their methylation status with gene expression. Furthermore, we evaluated the role of ERα in the DNA methylation process and the role of altered gene expression of epigenetic markers in the seminal vesicle of male mice.

Materials and Methods
=====================

*Chemicals*. Diethylstilbestrol (DES; CAS no. 56-53-1) was purchased from Sigma-Aldrich (St. Louis, MO).

*Animals and neonatal treatment*. All animal studies were conducted in accordance with the *Guide for the Care and Use of Laboratory Animals* ([@r29]) and approved by the National Institute of Environmental Health Sciences Animal Care and Use Committee. Animals were treated humanely and with regard for alleviation of suffering. Mice were housed under constant environmental conditions (22 ± 1°C; relative humidity, 40--60%; 12:12-hr light:dark cycle). Mice received autoclaved feed (NIH31 pelleted chow; Zeigler Brothers, Gardners, PA) and reverse-osmosis deionized water *ad libitum*. They were housed in polycarbonate caging with hardwood bedding (SaniChip; PJ Murphy Forest Products, Montville, NJ) with autoclaved environmental enrichment (Nestlets; Ancare, Bellmore, NY). For WT mice, 8- to 12-week-old pregnant C57BL/6 females (*n* = 30) were obtained from Charles River Laboratories (Wilmington, MA). ERα-null mice (αERKO) were generated by breeding C57BL/6 heterozygous (ERα^+/--^) animals as described previously ([@r13]). On the day of birth (considered day 1), male pups from multiple litters were pooled and randomly distributed among 8- to 12-week-old CD-1 foster mothers with eight pups per dam. For neonatal treatment, pups were treated each morning of days 1--5 by subcutaneous injection with either DES dissolved in corn oil (2 μg/pup/day; 0.02 cc) DES group) or an equal volume of corn oil (vehicle group). Mice (WT and αERKO) were weaned and genotyped on day 21. After weaning, mice were housed two to four per cage by treatment group. The genotyping was performed by polymerase chain reaction (PCR) on DNA extracted from tail biopsy using previously described methods ([@r13]).

SVs were collected at weeks 3, 5, and 10 from WT mice (vehicle and DES groups) and only at week 10 from both treatment groups of αERKO mice ([Figure 1](#f1){ref-type="fig"}). On the day of tissue collection, mice were euthanized by CO~2~ inhalation and SVs were removed immediately. A portion of each SV was fixed in Bouins solution for immunohistochemistry. The remaining SV tissues were snap frozen and stored at --80°C until use.

![Timeline for neonatal treatment \[DES (2 μg/day) or corn oil vehicle (2 μg/day)\] and tissue collection.](ehp.1307351.g001){#f1}

*LF immunohistochemistry.* For immunohistochemistry, SVs were fixed in Bouin's solution, processed through graded ethanol, embedded in paraffin, and sectioned at 7 μm. See Supplemental Material, p. 4, for additional details. After deparaffinization, slides were immunostained using anti-LF antibody (sc-14434; Santa Cruz Biotechnology, Santa Cruz, CA) and the AEC (aminoethyl carbazole) kit (Zymed Laboratory, South San Francisco, CA) according to the manufacturer's instructions. Tissues were then counterstained with hematoxylin (Sigma-Aldrich).

*RNA extraction and real-time PCR*. Total RNA samples were extracted from frozen SV tissue from individual mice using the RNeasy Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's protocol. First-strand cDNA synthesis was performed using Superscript Reverse Transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. We measured mRNA levels *Svs4*, *Ltf*, *Pgr* (progesterone receptor), *Stat3*, *Stat5a*, *DNMT1*, *DNMT3A*, *DNMT3B*, *MeCP2*, *MBD2*, *MBD3*, *HDAC1*, and *HDAC2* using SYBR green assays (Applied Biosystems, Foster City, CA). The sequences of primers used in real-time PCR are provided in Supplemental Material, Table S1. Cycle threshold (Ct) values were obtained using the ABI PRISM 7900 Sequence Detection System and analysis software (Applied Biosystems). The experiments were repeated three times, and results are presented as the fold increase (± SE) calculated relative to the vehicle WT group at week 5.

*Identification of potential ERE sequences and CpGs*. We downloaded the genomic sequence of the gene promoters (*Svs4*, *Ltf*, and *Pgr*) from the UCSC Genome Browser (<http://genome.ucsc.edu>; build mm10). A putative ERE sequence with the position weight matrix (PWM) constructed from 48 experimentally identified EREs (15 bp in length) was scanned using GADEM software ([@r32]; [@r35]). CpGs were identified using EpiDesigner software (<http://www.epidesigner.com/>).

*DNA extraction and bisulfite conversion--sequencing PCR*. Genomic DNA (400--500 ng) was extracted from frozen SV tissue of individual mice using a Tissue Blood Kit (QIAGEN) according to the manufacturer's protocol. Bisulfite conversion--sequencing PCR primers (see Supplemental Material, Table S2) were designed using EpiDesigner. Bisulfite conversion--sequencing PCR was performed using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA) following the manufacturer's instructions. The PCR products were resolved on a 2% agarose gel and purified using a QIAquick Gel Extraction Kit (QIAGEN).

*Cloning and sequencing bisulfite-treated DNA*. Purified PCR product from individual mice was subcloned into the pCR-TOPO-XL vector using the TOPO XL PCR Cloning Kit (Invitrogen) following the manufacturer's instructions. Six or more clones were selected and sequenced for each sample. We performed the sequencing analysis of bisulfite-treated DNA using CpGviewer software (<http://dna.leeds.ac.uk/cpgviewer/>) ([@r7]). Data presented represent three individual mice per treatment group.

*Statistical analysis*. One-way analysis of variance (ANOVA) with Dunnett's multiple comparison test (*p* \< 0.05 and *p* \< 0.01) and two-way ANOVA with Bonferroni posttest (*p* \< 0.001) were performed using GraphPad Prism, version 6.00 (GraphPad Software, San Diego, CA, USA).

Results
=======

*DES-altered levels of* Svs4 *and* Ltf *gene expression are ER*α *dependent.* To verify DES alteration of androgen- or estrogen-dependent genes in SV tissues, we examined *Svs4* (a male-specific gene) and *Ltf* (a female-specific gene) in adult WT and αERKO male mice treated neonatally with either DES or vehicle. The *Svs4* gene is highly expressed in the WT SV. In SVs collected 10 weeks after neonatal treatment, the expression level of *Svs4* in the DES group was \< 10% that in the vehicle group ([Figure 2A](#f2){ref-type="fig"}). *Svs4* expression was much lower in αERKO vehicle group than in WT vehicle group. In αERKO mice, we observed no significant change between DES- and vehicle-treated mice ([Figure 2A](#f2){ref-type="fig"}). In addition, at week 5, expression of *Svs4* was lower in both WT vehicle and DES groups than in WT vehicle group at week 10 (data not shown).

![Effect of neonatal DES exposure on *Svs4* (*A*) or *Ltf* (*B*) gene expression in SVs of mice 10 weeks after treatment with vehicle or DES. Total RNA samples were extracted from SV tissues of three individual WT or αERKO mice per treatment group, and mRNA levels were quantified by real time-PCR. Data shown represent mean fold change (± SE) relative to SVs from WT vehicle-treated mice at week 5. ^\#^*p* \< 0.001 by two-way ANOVA with Bonferroni posttest.](ehp.1307351.g002){#f2}

At week 10, we found minimal *Ltf* gene expression in SVs from both WT and αERKO mice treated with vehicle ([Figure 2B](#f2){ref-type="fig"}). Interestingly, in DES-treated animals, we found high levels of *Ltf* gene expression in WT but not αERKO SVs. In addition, when we used immunohistochemical staining to examine the levels of LF protein, we found strong staining in SVs from DES-treated WT but not DES-treated αERKO mice (see Supplemental Material, Figure S1). These data show that ERα mediates DES-induced alterations of gene expression in the SV of adult male mice.

*Methylation status of four specific CpGs in the* Svs4 *gene promoter: effect of DES and ER*α *on change from methylated to unmethylated during development.* Using data from UCSC Genome Browser, we found four CpGs (--160, --237, --306, and --367) located in the *Svs4* gene promoter close to the transcription start site ([Figure 3A](#f3){ref-type="fig"}). To determine whether DNA methylation correlates with *Svs4* transcription, we used bisulfite sequencing to examine the methylation status of these four CpGs in WT SVs at weeks 3, 5, and 10. In vehicle group, \> 70% of these CpGs were methylated at weeks 3 and 5, but only 18% of the same CpGs were methylated at week 10 ([Figure 3B](#f3){ref-type="fig"}, top). However, in the DES-treated WT mice, about 60% of the CpGs were methylated at week 3 or 5 and 84% were methylated at week 10 ([Figure 3B](#f3){ref-type="fig"}, bottom). The maintenance of methylation at these CpGs is consistent with down-regulation of the *Svs4* gene in the DES WT group at week 10 ([Figure 2A](#f2){ref-type="fig"}).

![The methylation status of *Svs4* changes during development after neonatal treatment with vehicle or DES. (*A*) Diagram depicting four CpGs in the mouse *Svs4* gene. (*B*,*C*) DNA methylation status of the *Svs4* gene in SVs from WT mice at weeks 3, 5, and 10 (*B*) and from αERKO mice at week 10 (*C*). Genomic DNA was extracted from SV tissues of individual mice, the region containing the four CpGs was amplified by PCR from bisulfite-treated genomic DNA, and the PCR product was subcloned into the pCR-TOPO-XL vector. The sequencing analysis was performed using CpGviewer. Each line of circles indicates an individual clone sequenced in the analysis. Data shown represent the results from three individual mice per group. The percentages of methylated/unmethylated (Me/un-me) CpGs represent the results from all four CpGs.](ehp.1307351.g003){#f3}

To examine the effects of ERα on the DNA methylation status of the *Svs4* gene promoter, we performed bisulfite conversion sequencing PCR with SV tissue collected from αERKO mice at week 10. In both vehicle and DES αERKO groups, \> 70% of the four CpGs were methylated ([Figure 3C](#f3){ref-type="fig"}). These results suggest that the lack of ERα and neonatal DES treatment each blocked the normal developmental alterations in the DNA methylation status of these four specific CpGs (--160, --237, --306, and --367) of the *Svs4* gene promoter. The observed alterations of DNA methylation correlate with gene expression.

*Methylation status of two specific CpGs in the* Ltf *gene promoter: effect of neonatal DES treatment on changes from methylated to unmethylated.* In the *Ltf* gene promoter, we found five CpGs (--449, --459, --470, --528, and --542) located close to a well-characterized ERE site (--324) ([@r36]; [@r37]) and the transcription start site ([Figure 4A](#f4){ref-type="fig"}). To determine whether the alteration of DNA methylation directly regulates *Ltf* gene transcription, we examined the methylation status of these five CpGs in the *Ltf* gene promoter in the WT SV collected at weeks 3, 5, and 10 after neonatal DES treatment. In the vehicle group, \> 90% of these CpGs were methylated, and the methylation pattern did not change during development, from weeks 3 to 10 ([Figure 4B](#f4){ref-type="fig"}, top). In SVs from the DES-treated WT mice, there were no changes in the methylation status at week 3 or week 5; however, at week 10, two specific CpGs (--449 and --459) changed from methylated to unmethylated ([Figure 4B](#f4){ref-type="fig"}, bottom). Loss of methylation at these CpGs is consistent with the up-regulation of *Ltf* gene expression in the DES group at week 10 ([Figure 2B](#f2){ref-type="fig"}).

![The methylation status of *Ltf* changes during development after neonatal treatment with vehicle or DES. (*A*) Diagram depicting five CpGs in the mouse *Ltf* gene promoter. (*B*,*C*) DNA methylation status of the *Ltf* gene in SVs from WT mice at weeks 3, 5, and 10 (*B*) and from αERKO mice at week 10 (*C*). Genomic DNA was extracted from SV tissues of individual mice, the region containing the five CpGs was amplified by PCR from bisulfite-treated genomic DNA, and the PCR product was subcloned into the pCR-TOPO‑XL vector. The sequencing analysis was performed using CpGviewer. Each line of circles indicates an individual clone sequenced in the analysis. Data shown represent the results from three individual mice per group. The percentages of methylated/unmethylated (Me/un-me) CpGs represent the results from two CpGs (--449 and --459).](ehp.1307351.g004){#f4}

We also examined the methylation status of the same five CpGs in the *Ltf* gene promoter in SVs from αERKO mice at week 10. In DES-treated mice, we found no change in the methylation status of two specific CpGs (--449 and --459) ([Figure 4C](#f4){ref-type="fig"}). These data suggest that DES altered the methylation status of these two CpGs in the *Ltf* gene promoter from methylated to predominantly unmethylated, and that the absence of ERα blocked this change.

*Differential effects of neonatal DES treatment on the expression levels of the epigenetic modifiers* DNMT3A, MBD2, *and* HDAC2. To examine whether the altered methylation patterns in SVs from mice treated neonatally with DES might be affected by the expression level of the epigenetic modifiers, we used real-time PCR to investigate the RNA levels of DNA methyltransferases, including DNMTs (*DNMT1*, *DNMT3A*, and *DNMT3B*) and MBDs (*MeCP2*, *MBD2,* and *MBD3*), as well as two histone modifiers (*HDAC1* and *HDAC2*). We examined the expression levels of these genes in SVs collected from WT mice at week 5 or week 10 after neonatal exposure to vehicle or DES.

At week 5, the expression level of *DNMT3A* was significantly increased in the DES group compared with the vehicle group, but at week 10, *DNMT3A* was lower in the DES group than in the vehicle group ([Figure 5A](#f5){ref-type="fig"}). However, the gene expression of *DNMT1* and *DNMT3B* was not significantly different between DES and vehicle groups in either week ([Figure 5A](#f5){ref-type="fig"}). At week 5, the expression level of *MeCP2* was much higher in the vehicle group, but this level was significantly lower in the DES group ([Figure 5B](#f5){ref-type="fig"}). However, we observed no significant difference in *MeCP2* gene expression between the vehicle and DES groups at week 10. *MBD2* expression at week 10 was significantly elevated in the DES group relative to the vehicle group at week 10. In addition, DES did not affect the expression of *MBD3* relative to vehicle at week 5 or week 10 ([Figure 5B](#f5){ref-type="fig"}).

![Gene expression levels of epigenetic markers DNMTs (*A*), MBDs (*B*), and HDACs (*C*) in WT SVs from mice treated neonatally with vehicle or DES. Total RNA samples were extracted from SV tissues of three individual WT or αERKO mice at week 5 or week 10 after neonatal treatment. Gene expression levels were quantified by real time-PCR. Data shown represent mean fold change (± SE) relative to SVs from WT vehicle-treated mice at week 5. \**p* \< 0.05, and \*\**p* \< 0.01 by one-way ANOVA with Dunnett's multiple comparison test.](ehp.1307351.g005){#f5}

Expression of the histone modification marker *HDAC2* was significantly increased in SVs from the DES group compared with the vehicle group at week 5 but not at week 10. In contrast, expression of *HDAC1* was not different in the DES group at either week 5 or week 10 ([Figure 5C](#f5){ref-type="fig"}). These findings suggest that alterations in gene expression of these epigenetic modifiers are correlated with changes in methylation status seen with neonatal DES treatment.

Discussion
==========

*Correlation between altered DNA methylation and the expression levels of specific genes in SVs of adult male mice neonatally treated with DES*. There is increasing interest in the effect of EDCs on human health ([@r23]). One of the earliest recognized EDCs, DES is still being used to study the possible effects of EDCs on reproductive organs. Previous studies in our laboratory observed alterations in male- and female-specific genes in adult male mice treated neonatally with DES ([@r12]; [@r61]). In the present study, we investigated the effect of neonatal DES treatment on DNA methylation patterns of *Svs4* (male-specific) and *Ltf* (female-specific) genes during development in SVs from WT and αERKO mice. One of the most significant findings of our study is a correlation between DNA methylation patterns and the levels of *Svs4* and *Ltf* gene expression in an ERα-dependent manner in DES-treated mice.

Previous studies have shown that the decrease in *Svs4* expression is not due to a significant change in the level of *AR* gene expression in the SVs of adult male mice neonatally treated with DES ([@r58]; [@r61]). SVS IV protein is found in the SVs of mice and rats and is regulated by androgen ([@r9]). In the present study, we used data from UCSC Genome Browser to analyze the Svs4 gene promoter. We found a putative Stat5a/5b binding site upstream (--132/--146 bp) and an Sp1 site downstream (+118/+128 bp) (see Supplemental Material, Figure S2). We found a predicted ERE site within the 2 kb of the transcription start site (+/--1 kb). However, the 4 bases of the palindrome differ from the 10 base consensus ERE (GGTCAnnnTGACC) (see Supplemental Material, Figure S2). [@r12] found that SV weight was significantly lower in DES-treated WT adult male mice but not in DES-treated αERKO mice. These data suggest that this effect is ERα dependent and might act through the nonclassical (tethered) mechanism.

In the SV tissues from rat, a methylation-sensitive restriction assay showed that seven potential methylation sites were largely methylated ([@r34]). In the present study, we found a normal developmental change in DNA methylation status at four specific CpGs (--160, --237, --306, and --367) of the *Svs4* gene promoter in WT SVs between week 3 and week 10. Furthermore, DES exposure and the absence of ERα both blocked the normal developmental demethylation of the *Svs4* gene; these changes in DNA methylation correlate with the gene expression findings in this study. This is the first report addressing the correlation between DNA methylation and expression of the *Svs4* gene in a mouse model, as well as a role for ERα in this process. Our results help to explain the relationships of epigenetic mechanisms and gene regulation.

The *Ltf* gene, a well-known female-specific ER target gene, is up-regulated by E2 in the female reproductive tract ([@r57]). In female mice, the early appearance of LF protein expression suggests that it may play an important role in the hormonal regulation of growth and differentiation of developing uterine tissues ([@r47]). In male mice, there is normally no *Ltf* gene expression, nor is there a potential role for this gene in SV tissues; however, *Ltf* is highly expressed after neonatal/prenatal DES exposure ([@r12]; [@r48]). E2 increases *Ltf* expression through a well-characterized ERE (--324) located upstream from the *Ltf* promoter transcription start site ([@r37]; [@r38]). Using chromatin immunoprecipitation (ChIP) quantitative PCR ([@r26]), we confirmed that ERα is bound to this ERE site (--324) in the *Ltf* gene promoter in SVs from 10-week-old WT mice with or without neonatal DES exposure. However, DES enhances the enrichment of ERα binding (data not shown). In addition, we found three predicted EREs and an Sp1 site in the region 1 kb upstream of the *Ltf* gene promoter (see Supplemental Material, Figure S3). Importantly, in SVs from male mice neonatally treated with DES, we found two specific CpGs (--449 and --459) upstream of the *Ltf* gene promoter that have altered DNA methylation status (from methylated to unmethylated). In a methylation analysis of the *Ltf* gene promoter in the CD-1 mouse uterus, [@r36] observed that prenatal DES exposure altered only one CpG site (CpG site --464, corresponding with CpG site --459 in our study), which changed from methylated to unmethylated; this finding suggsts that the effects of DES on DNA methylation are tissue specific. Also in that study ([@r36]), DNA methylation status in the *Ltf* promoter of the uterus of 3-week-old CD-1 mice changed from methylated to unmethylated at three specific CpGs (--475, --533, and --547), corresponding with CpG sites --470, --528, and --542 in the present study. At week 3 in the present study, we observed no developmental changes at these three CpGs (--470, --528, and --542) in SV tissues from C57BL/6 male mice. These findings suggest that there are sex and/or strain differences in the DNA methylation patterns of the *Ltf* gene in the mouse reproductive organs.

Next, we examined the gene expression level of *Pgr*, a well-known ER target gene, in SVs. The gene profile showed differences in expression of the *Pgr* gene in vehicle-treated WT and αERKO mice due to the lack of ERα, but there were no significant changes of *Pgr* expression in the SVs of DES-treated WT and αERKO mice (see Supplemental Material, Figure S4A). Using EpiDesigner software, we found a high CpG content, with 20 CpGs located in the introns of the *Pgr* gene between +661 and +886. When examining the DNA methylation patterns, we found that almost 100% of these CpGs were unmethylated in SVs of both vehicle and DES groups at week 10 (see Supplemental Material, Figure S4B), suggesting that the DNA methylation patterns of the *Pgr* gene correlate with its gene expression. There might be other CpGs of the *Pgr* gene involved in reduction of gene expression in αERKO SVs compared with WT SVs; however, in the αERKO mouse, it is most likely that the lack of ERα and the hormone responsiveness in the SV explain the lower expression of *Pgr*.

The growth-hormone-signaling--activated transcription factors *Stat3* and *Stat5a* regulate estrogen signaling ([@r63]; [@r26]). In the present study, we found that the expression levels of *Stat3* and *Stat5a* in SVs from DES-treated WT mice were significantly increased at week 5 but not at week 10 (see Supplemental Material, Figure S5). Furthermore, when we focused our efforts on ERα, we reconfirmed that there were no changes in *AR* gene expression in SVs from DES-treated mice compared with those treated with vehicle (data not shown), suggesting that alterations of *Pgr* in SVs of DES-treated males occurred through another nuclear receptor. In addition, the level of serum testosterone is lower in adult αERKO males compared with WT males, and this may regulate the levels of *Svs4* and *Ltf* gene expression ([@r61]).

*Neonatal DES treatment alters the expression levels of epigenetic modifiers in the SVs of male mice*. There are two main epigenetic mechanisms/modifications: DNA methylation and histone modification ([@r18]). The enzymatic machinery for DNA methylation is composed mainly of three DNMTs: *DNMT1*, *DNMT3A*, and *DNMT3B* ([@r1]). In recent years, the levels of these enzymes have been measured in reproductive organs and used as DNA methylation markers after exposure to EDCs, such as DES and bisphenol A (BPA) ([@r5]; [@r54], [@r55]). In mice neonatally treated with DES, expression levels of *DNMT1*, *DNMT3A*, and *DNMT3B* in the uterus and epididymis change dynamically ([@r54], [@r55]). In the present study we found that only *DNMT3A* expression increased in the SVs mice neonatally exposed to DES (at the 5-week time point), suggesting that *DNMT3A* is involved in epigenetic programming at different periods of development. Interestingly, expression of *DNMT3A* and *DNMT3B* was much lower in the DES group than in the vehicle group at week 10, indicating that these epigenetic modifiers change dynamically during DES exposure.

The MBD family of proteins (e.g., *MeCP2*, *MBD2*, and *MBD3*) play an important role in transcriptional repression (Bird et al. 1999; [@r22]; [@r59]). We found a significant increase in *MBD2* expression in DES-treated mice at week 10 in the present study. This finding is in agreement with the study of [@r56], which found that *MBD2* expression increased after neonatal E2/BPA exposure in the rat prostate gland.

The histone modification markers (*HDACs*) are evolutionarily conserved enzymes that remove acetyl modifications from histones and play a central role in epigenetic gene silencing ([@r21]). [@r15] found that *HDAC1* controlled embryonic stem cell differentiation, but they observed no effect of *HDAC2.* In DES-treated mice in the present study, we observed that *HDAC2* expression was increased significantly in SVs at week 5. These data indicate that the involvement of these histone modifiers in epigenetic programming could be cell- and tissue-type specific. The observed changes in these proteins suggest that the effects of DES on DNA methylation of target genes may be more widespread, and a global analysis needs to be performed in future studies.

Conclusions
===========

In the present study we found an association between DNA methylation and gene expression for the *Svs4* and *Ltf* genes. A working model of this study is shown in Supplemental Material, Figure S6. Four specific CpGs (--160, --237, --306, and --367) in the *Svs4* gene changed from methylated to unmethylated during development; however, methylation changes at these CpGs were not observed in mice neonatally treated with DES. Normal methylation changes in the *Svs4* gene were not seen in αERKO mice, suggesting that ERα may play an active role in the methylation changes. In WT mice, DES altered the DNA methylation status from methylated to unmethylated at two specific CpGs (--449 and --459) in the *Ltf* gene promoter. In addition, DES treatment appeared to significantly regulate the expression levels of the epigenetic modifiers *DNMT3A*, *MBD2*, and *HDAC2*. Taken together, these results are consistent with the hypothesis that DES-induced toxicity is mediated by ERα alteration of target gene methylation patterns and through changes in gene expression of three epigenetic modifiers in the SV of adult male mice neonatally treated with DES.

Supplemental Material
=====================

###### 

Click here for additional data file.
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